EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 28 November 2024

Urgent policy reforms needed to support the future of Europe’s biopharma SMEs, says EFPIA

Read the full article here

Europe needs to “catch up” and develop policies and funding streams to support small and medium size enterprises (SMEs) working in the biopharmaceutical sector.

New research published this week argues that dedicated strategies are needed to help emerging companies succeed in the EU. A lack of dedicated EU funding and investment means that SMEs – companies often working at the very cutting edge of medical research – are increasingly looking to more supportive environments outside of Europe.

Analysis from the SME landscape in Europe concurs with President von der Leyen’s commitment in her political guidelines to boost the EU life science sector during the next mandate, and is also supported by the Draghi’s report on competitiveness.

EFPIA Conference – Don’t miss your last chance to register!

Join leaders from the pharmaceutical industry, policymakers, patient advocates, and healthcare experts to discuss how we can work together to build a healthier, more competitive Europe.

Discover the programme and register here.

Watch the recording of Nathalie Moll's intervention at the POLITICO Health Care Summit

Here is the recording of the panel discussion, "Pharma Legislation: Balancing Protection, Access, and Innovation," featuring:

Marco Greco, President, European Patients' Forum (EPF)
Edward James-Smith, Head of EU Affairs, Ministry of the Interior and Health, Denmark
Nathalie Moll, Director General, EFPIA
Katarzyna Piotrowska-Radziewicz, Director, Department of Drug Policy and Pharmacy, Ministry of Health, Poland

Translating innovation into access for ATMPs: third EU-Innovation network multi-stakeholder meeting

On 15 November, the EU-Innovation Network (EU-IN) and the Italian Medicines Agency (AIFA) held a multi-stakeholder meeting to discuss how innovation in the development of Advanced Therapy Medicinal Products (ATMPs) can be translated into effective and safe therapies at the point of care in Europe.

Watch the recording here.

What we are reading

Align pharma reform with EU’s competitiveness focus, says Roche pharma chief
On 27 November 2024 (Euractiv)

The EU’s pharma reform must be viewed from a fresh perspective in the context of the new EU mandate’s focus on competitiveness,... Read more

Innovating for impact: Shaping the future of rare disease treatment
On 22 November 2024 (Euronews)

Millions of Europeans are living with rare diseases for which no treatment options exist. Out of the 6,000 to 7,000... Read more

Europe is central not just as a market but as a hub for pioneering advancements in healthcare...
On 20 November 2024 (Pharma Boardroom)

Europe and Canada (EUCAN) have an essential role in Takeda’s global mission to advance healthcare innovation. Ricardo... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu